Celgene Corporation

Celgene
86 Morris Ave
Summit, NJ, 07901-3915  United States
(908) 673-9000
Company Type: Corporation Subsidiary

D&B Business Directory

Celgene lines up cells and genes to create good health. The biopharmaceutical company's lead product is Revlimid, which is approved in the US, Europe, and other select markets as a treatment for multiple myeloma (bone marrow cancer). Revlimid also is used to treat a blood disorder called myelodysplastic syndrome (MDS). The company's second-biggest seller is Pomalyst/Imnovid, which is approved in various markets for the treatment of multiple myeloma. Other products include chemotherapy agent Abraxane. The firm has other drugs in development that combat inflammatory diseases and cancer. Bristol-Myers Squibb acquired Celgene in a $74 billion deal in 2019.

Try D&B Hoovers Free
Corporation Subsidiary
Doing Business As
Celgene
Website
Address
86 Morris Ave
Summit ​, NJ, 07901-3915
United States
See other locations
Phone
(908) 673-9000
Company Description

Celgene lines up cells and genes to create good health. The biopharmaceutical company's lead product is Revlimid, which is approved in the US, Europe, and other select markets as a treatment for multiple myeloma (bone marrow cancer). Revlimid also is used to treat a blood disorder called myelodysplastic syndrome (MDS). The company's second-biggest seller is Pomalyst/Imnovid, which is approved in various markets for the treatment of multiple myeloma. Other products include chemotherapy agent Abraxane. The firm has other drugs in development that combat inflammatory diseases and cancer. Bristol-Myers Squibb acquired Celgene in a $74 billion deal in 2019.

Key Principal
Mark J Alles See more contacts
Industry
D&B Hoovers Logo

For dynamic search and list-building capabilities, real-time trigger alerts, comprehensive company profiles, and valuable research and technology reports try D&B Hoovers for free!

Financial Statements

Revenue in USD

Annual Revenue2018
$15.28 billion USD

Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.

Competitor Profiles

See detailed profiles for insights and prospects on this company's top competitors.

Company Snapshot

Essential information for a successful call

  •  EMPLOYEES (This Site) 211
  •  EMPLOYEES (All Sites) 8,852
  •  REVENUE (MIL USD) 15,281
  • Year Started 1986
  • Incorporated 1986
  • FISCAL YEAR END DEC

Get in Touch with 7 Principals* and 2,425 Contacts

A D&B Hoovers Subscription is your foot in the door to Celgene Corporation contact information.
  • Mark J Alles
    Chairman of the Board and Chief Executive Officer
  • MATTHEW RODEN
    President
  • DAVID V ELKINS
    Executive Vice President and Chief Financial Officer
  • JONATHAN BILLER
    Executive Vice President and General Counsel

Want more contacts like these available directly in your inbox? Install D&B Email IQ to access your next prospects!

Free Install

Related Products

Grow Business FasterLearn More
D&B Finance Analytics Credit IntelligenceIntelligent Risk ManagementLearn More
Free Microsoft Outlook plugin to drive efficiency with on-demand sales intelligenceFree Install

Get full access to D&B Hoovers

With a Hoovers subscription you can get a comprehensive view of Celgene Corporation

Celgene Corporation*

7
Principals
See who the company's key decision makers are
2,425
Contacts
Reach the right people with access to detailed contact information.
398
Corporate Relations
Get the big picture on a company's affiliates and who they do business with.
9
Close Industry Peers
See similar companies for insight and prospecting.
*Contacts and Principals counts are estimates and may differ from the actual number of contacts available in D&B Hoovers.